CrystalGenomics Invites Co (XKRX:083790) ROCE % : -14.65% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is CrystalGenomics Invites Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CrystalGenomics Invites Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -14.65%.

CrystalGenomics Invites Co ROCE % Historical Data

The historical data trend for CrystalGenomics Invites Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CrystalGenomics Invites Co ROCE % Chart

CrystalGenomics Invites Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-13.01

-3.37

-5.15

-8.53

-22.85

CrystalGenomics Invites Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-7.29	-59.97	37.64	-61.50	-14.65

CrystalGenomics Invites Co ROCE % Calculation

CrystalGenomics Invites Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-49057.333	/	( ( (322613.064 - 80836.746)	+	(243115.542 - 55547.659) )	/ 2 )
	=	-49057.333	/	( (241776.318	+	187567.883)	/ 2 )
	=	-49057.333	/	214672.1005
	=	-22.85 %

CrystalGenomics Invites Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-26843.456	/	( ( (243115.542 - 55547.659)	+	(236309.116 - 57507.535) )	/ 2 )
	=	-26843.456	/	( ( 187567.883	+	178801.581 )	/ 2 )
	=	-26843.456	/	183184.732
	=	-14.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

CrystalGenomics Invites Co (XKRX:083790) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CrystalGenomics Invites Co ROCE % Related Terms

Thank you for viewing the detailed overview of CrystalGenomics Invites Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CrystalGenomics Invites Co (XKRX:083790) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CrystalGenomics Invites Co Ltd (XKRX:083790) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5F, A-dong, Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi, KOR, 463-400

Website

http://www.crystalgenomics.com

CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.

CrystalGenomics Invites Co (XKRX:083790) Headlines

No Headlines